Treats overactive bladder with symptoms of urge urinary incontinence, urgency, and…. ANDA 213346, held by Sunshine. Solifenacin Succinate.
As of Nov 16, 2026, ANDA 213346 (Solifenacin Succinate), held by Sunshine, was first approved by FDA on Apr 13, 2020, with 0 approved supplements and 0 published complete response letters.
Solifenacin succinate is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 13, 2020 | Original application | Approved | None posted |
| Solifenacin Succinate5MG · tablet;oral | Solifenacin Succinate | Rx |
| Solifenacin Succinate10MG · tablet;oral | Solifenacin Succinate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters